
    
      This is a multi-center, randomized, double-blind, allopurinol and placebo controlled,
      parallel, 5 arms, dose response, bridging study of 4 weeks duration.

      If subjects pass the screening evaluation after submitting a signed informed consent, they
      will be randomly assigned to one of the five treatment regimens; febuxostat 40mg, 80mg,
      120mg, placebo or allopurinol 300mg. Colchicine 0.6mg QDis given to minimize the risk of gout
      flares during the washout/run-in period and during the double study period.
    
  